ANRO NYSE
Alto Neuroscience, Inc.
1W: -5.0%
1M: -13.1%
3M: -13.2%
YTD: +39.7%
1Y: +110.7%
$23.19
+1.08 (+4.88%)
Weekly Expected Move ±7.9%
$19
$20
$22
$24
$25
Credit Risk of going bust: lower than 60% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Alto Neuroscience, Inc. would be worth roughly what it owes.
Total debt $7.0M against a stock market value of $910.0M.
Distance to default 6.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.4M (short-term plus half of long-term), stock volatility 78.7%; Altman Z'' 7.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.8%), Alto Neuroscience, Inc. would be worth roughly what it owes.
Total debt $7.0M against a stock market value of $910.0M.
Distance to default 6.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.4M (short-term plus half of long-term), stock volatility 78.7%; Altman Z'' 7.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (33)
Alto Neuroscience (NYSE:ANRO) Shares Gap Up on Analyst Upgrade
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
Alto Neuroscience (NYSE: ANRO) CFO sells shares under trading plan
10 small-cap healthcare stocks with the strongest momentum grades
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from Analysts
AWM Investment Company Inc. Purchases New Holdings in Alto Neuroscience, Inc. $ANRO
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Still a Buy?
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High on Analyst Upgrade
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Analysts
Alto Neuroscience announces pricing of $100M underwritten registered direct offering of common stock
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $35.14 Consensus Price Target from Analysts
Equities Analysts Set Expectations for ANRO Q1 Earnings
Alto Neuroscience (NYSE:ANRO) Shares Gap Down Following Analyst Downgrade
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Wednesday's After-Market Session
Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Brokerages
Q1 EPS Forecast for Alto Neuroscience Reduced by Analyst
Alto Neuroscience announces $120M private placement financing
Earnings Scheduled For March 16, 2026
Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06
12 Health Care Stocks Moving In Monday's After-Market Session
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Brokerages
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why
Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08